Suppr超能文献

庆大霉素和妥布霉素的血液透析清除率及清除情况。

Hemodialysis elimination rates and clearance of gentamicin and tobramycin.

作者信息

Matzke G R, Halstenson C E, Keane W F

出版信息

Antimicrob Agents Chemother. 1984 Jan;25(1):128-30. doi: 10.1128/AAC.25.1.128.

Abstract

The apparent hemodialyzer elimination rate constant and clearance for gentamicin and tobramycin were determined during 100 routine hemodialysis treatments in 49 patients. Three different dialyzers (CDAK 3500, CF 1211, and CF 1511), which vary in membrane composition, surface area, and thickness, were evaluated. The elimination rate constant in each patient was calculated from the slope of the log serum concentration-time curves. Two different elimination rate constants for each patient were derived, one during hemodialysis (KT) and one off hemodialysis (K). The hemodialyzer elimination rate constant (KD) for each dialyzer was calculated as the difference between these two values. The hemodialyzer clearance (Cd) was calculated by multiplying the hemodialyzer elimination rate constant by the volume of distribution of the patient. The KDS of gentamicin and tobramycin by the three dialyzers were significantly different. The gentamicin KD of the CDAK 3500 was lower than the values of the CF 1211 and CF 1511 (0.086 versus 0.123 versus 0.131 h-1, respectively). The Cd of the CDAK 3500 for gentamicin was also significantly lower than that of the CF 1511. Although the CdS of tobramycin for the CF 1211 and CF 1511 were 24 and 43% greater than that for the CDAK 3500, these differences were not statistically significant. The KD and Cd of tobramycin were greater than those of gentamicin for all three dialyzers. These data demonstrate that commonly used hemodialyzers vary markedly with respect to their elimination and clearance characteristics of gentamicin and tobramycin. Clinically, these observations may be helpful in designing the correct dose of gentamicin and tobramycin to achieve maximum drug safety and efficacy in hemodialysis patients.

摘要

在对49例患者进行的100次常规血液透析治疗过程中,测定了庆大霉素和妥布霉素的表观血液透析器清除率常数及清除率。评估了三种不同的透析器(CDAK 3500、CF 1211和CF 1511),它们在膜组成、表面积和厚度方面存在差异。根据血清浓度-时间对数曲线的斜率计算每位患者的清除率常数。每位患者得出两个不同的清除率常数,一个是血液透析期间的(KT),另一个是非血液透析期间的(K)。每个透析器的血液透析器清除率常数(KD)计算为这两个值的差值。血液透析器清除率(Cd)通过将血液透析器清除率常数乘以患者的分布容积来计算。三种透析器对庆大霉素和妥布霉素的KDS有显著差异。CDAK 3500的庆大霉素KD低于CF 1211和CF 1511的值(分别为0.086对0.123对0.131 h-1)。CDAK 3500对庆大霉素的Cd也显著低于CF 1511。尽管CF 1211和CF 1511对妥布霉素的CdS分别比CDAK 3500高24%和43%,但这些差异无统计学意义。对于所有三种透析器,妥布霉素的KD和Cd均大于庆大霉素。这些数据表明,常用的血液透析器在庆大霉素和妥布霉素的清除及清除率特征方面存在显著差异。临床上,这些观察结果可能有助于设计正确的庆大霉素和妥布霉素剂量,以在血液透析患者中实现最大的药物安全性和疗效。

相似文献

5
Heterogeneity in gentamicin clearance between high-efficiency hemodialyzers.
Am J Kidney Dis. 1994 Jan;23(1):47-51. doi: 10.1016/s0272-6386(12)80811-0.

引用本文的文献

2
Pharmacokinetics of gentamicin in hemodialysis patients: a comparative study between diabetic and non-diabetic patients.
Int Urol Nephrol. 2009;41(3):663-9. doi: 10.1007/s11255-008-9456-2. Epub 2008 Sep 3.

本文引用的文献

3
Supplementary dose after hemodialysis.血液透析后的补充剂量。
Nephron. 1982;30(3):220-7. doi: 10.1159/000182465.
4
Rebound gentamicin levels after hemodialysis.血液透析后的庆大霉素反弹水平。
Ther Drug Monit. 1982;4(1):99-101. doi: 10.1097/00007691-198204000-00015.
5
Gentamicin and tobramycin dosing guidelines: an evaluation.庆大霉素和妥布霉素给药指南:一项评估
Drug Intell Clin Pharm. 1983 Jun;17(6):425-32. doi: 10.1177/106002808301700604.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验